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Abstract 
Background: Acute graft-versus-host disease (aGVHD) remains a major obstacle against favorable clinical outcomes 
following allogeneic hematopoietic stem cell transplantation (allo-HSCT). T helper cells including Th17 play key roles 
in aGVHD pathogenesis. Donor regulatory T cell (Tregs) adoptive therapy reduces aGVHD without weakening graft-
versus-leukemia effect (GVL) in both mouse and human, although the purification and ex vivo expansion of Tregs in 
clinical scenarios remain costly and technically demanding. Hypoxia-inducible factor 1 alpha (HIF-1α) is a key mol-
ecule switch that attenuates Treg but promotes Th17 development. However, whether pharmacological inhibition of 
HIF-1α reduces aGVHD via increasing Treg development and diminishing Th17 responses remains unexplored.
Methods: By using alloantigen-specific mixed lymphocyte culture and murine models of aGVHD and GVL, we evalu-
ated the impacts of HIF-1α inhibition by echinomycin on the alloantigen-specific CD4 T cell responses ex vivo, as well 
as on aGVHD and GVL effect following allo-HSCT.
Results: Ex vivo echinomycin treatment resulted in increased number of Tregs in the culture as well as reduced 
alloantigen-specific Th17 and Th1 responses. In vivo echinomycin treatment reduced GVHD scores and prolonged 
survival of mice following allo-HSCT, which is associated with increased number of donor Tregs and reduced number 
of Th17 and Th1 in lymphoid tissues. In murine model of leukemia, echinomycin treatment preserved GVL effect and 
prolonged leukemia free survival following allo-HSCT.
Conclusions: Echinomycin treatment reduces aGVHD and preserves GVL effect via increasing donor Treg develop-
ment and diminishing alloantigen-specific Th17 and Th1 responses following allo-HSCT, presumably via direct inhibi-
tion of HIF-1α that results in preferential Treg differentiation during alloantigen-specific CD4 T cell responses. These 
findings highlight pharmacological inhibition of HIF-1α as a promising strategy in GVHD prophylaxis.
Keywords: Acute graft-versus-host disease, Graft-versus-leukemia effect, Hypoxia-inducible factor 1 alpha, 
Echinomycin, Regulatory T cells, Th17 cells
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Allo-HSCT remains the only therapeutic strategy that has 
the potential to cure hematopoietic malignancies includ-
ing leukemia [1, 2]. Therapeutic effects of allo-HSCT 
rely largely on GVL effect where donor T cells eradicate 
residual leukemia cells primarily in an alloantigen spe-
cific manner and thus prevent leukemia from relapse [3, 
4]. However, aGVHD that is closely associated with GVL 
effect has been a huge challenge to favorable clinical out-
comes following allo-HSCT [1, 4]. Similar to GVL effect, 
aGVHD results from donor T cell-mediated alloantigen-
specific immune responses [5]. It has been shown that 
alloantigen-specific Th1 and Th17 cells contribute signifi-
cantly to systemic inflammation and target tissue dam-
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cell depletion from hematopoietic stem cell (HSC) graft 
represents an efficient strategy in aGVHD prophylaxis. 
Unfortunately, accumulating data have shown that such 
a pan-T cell targeting regimen results in weakened GVL 
effect as evidenced by the increased risk of graft failure, 
delayed immune reconstitution, and leukemia relapse 
[9–11]. For these reasons, improved prophylactic and/
or therapeutic strategies are in urgent need to separate 
aGVHD and GVL.
In recent years, infusion of donor Tregs has been 
reported as a promising aGVHD prophylactic strategy in 
both mouse and human without weakening GVL effect 
[12–14]. In one of these studies, adoptive transfer of 
donor Tregs prevented GVHD in human subjects receiv-
ing allo-HSCT, with improved lymphoid reconstitution 
and immunity to opportunistic pathogens without weak-
ening GVL effect [13]. In line with this, clinical studies 
revealed that higher number of Tregs in HSC graft are 
associated with reduced GVHD, and abundance of Foxp3 
gene expression was significantly higher in non-GVHD 
than GVHD patients following allo-HSCT [15, 16]. These 
studies provided compelling evidence that prevention 
of GVHD without weakening GVL can be achieved via 
increasing the number of donor Tregs in HSC recipients. 
However, current clinical protocols for Treg purifica-
tion and ex vivo expansion are costly and highly techni-
cally demanding [14]. Moreover, Tregs purified and/or 
expanded by using various protocols may represent dif-
ferent subtypes and thus have inconsistent functions in 
preventing GVHD and/or preserving GVL effect [17]. 
These obstacles remain challenges to the wide applica-
tion of Treg infusion as a GVHD prophylactic regimen in 
clinical scenarios.
HIF-1α is a key metabolic sensor regulating the differ-
entiation of CD4 T cells [18, 19]. It has been shown that 
HIF-1α inhibits Treg development via targeting Foxp3 
for proteasomal degradation [18]. Concurrently HIF-1α 
enhances Th17 development via transcriptional activa-
tion of RORγt [18, 20]. As Tregs play regulatory roles not 
only in Th17 responses but also in other T helper cells 
including Th1 cells [21], HIF-1α serves as a molecular 
switch between Treg-mediated immune homeostasis and 
T helper cell-mediated immune responses and immu-
nopathology. Indeed, mice with HIF-1α deficiency in 
CD4 T cells were resistant to experimental autoimmune 
encephalitis model, a Th17 dependent autoimmune dis-
ease. Such a phenotype is associated with increased Treg 
development and reduced Th17 responses [18]. Echino-
mycin, a small molecule HIF-1α inhibitor, reduces target 
molecule binding ability of HIF-1α [22, 23]. Inhibition 
of HIF-1α by echinomycin reduced Th17 development 
and persistence, which is consistent to that observed in 
HIF-1α deficient CD4 T cells [24]. However, it remains 
unexplored whether HIF-1α inhibition by echinomycin 
reduces aGVHD by promoting Tregs and diminishing 
Th17 development.
By using murine models of aGVHD and GVL, we show 
here that HIF-1α inhibition by echinomycin treatment 
significantly reduces aGVHD without weakening GVL, 
resulting in prolonged leukemia free survival. This phe-
notype is associated with increased donor Tregs and 
diminished Th17 and Th1 responses in lymphoid organs. 
Our study highlight the significance of HIF-1α in Treg/
Th17 balance during aGVHD pathogenesis, and that 
pharmacological inhibition of HIF-1α represents a prom-




Wild-type C57BL/6J and Balb/c mice (female, 6–8 weeks 
of age) were purchased from the Joint Ventures Sipper 
BK Experimental Animal Co. (Shanghai, China). Mice 
were housed in specific pathogen-free conditions, and all 
experimental manipulations were conducted in accord-
ance with the National Institute of Health Guide for the 
Care and Use of Laboratory Animals along with approval 
from the Scientific Investigation Board of the Shenzhen 
People’s Hospital.
Leukemia cell line
A20 leukemia cells were a kind gift from Dr. Kai Sun 
from Henan Provincial People’s Hospital. Cells were cul-
tured at 37 °C in a 5% CO2 incubator in RPMI 1640 cul-
ture media supplemented with 10% fetal bovine serum 
(HyClone Laboratories, South Logan, UT, USA), penicil-
lin and streptomycin. To determine the apoptosis of A20 
cells, cells were cultured in triplicates in 24-well plates for 
24 h in the presence of echinomycin at indicated concen-
trations, followed by Annex V and PI staining. For colony 
forming assay, A20 cells were cultured in the presence of 
echinomycin at indicated concentrations for 24  h. Cells 
were then washed to remove echinomycin, and sus-
pended in Methocult H4230 (STEMCELL Technologies, 
Vancouver, BC, Canada) at 1  ×  103 cells/mL, plated in 
24-well plate in triplicates and cultured for 7–14 days at 
37  °C in a 5% CO2 incubator. The colony forming units 
(CFU) per well was counted and representative pictures 
of cellular clusters were taken under a DMI6000 inverse 
microscope (Leica Biosystems, Heidelberg, Germany).
Generation of bone marrow derived dendritic cells
Murine bone marrow derived dendritic cells (BMDCs) 
were generated as previously described [25, 26]. Briefly, 
murine bone marrow mononuclear cells were obtained 
from femur bones followed by red blood cell lysis. Bone 
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marrow cells were then cultured for 7  days in RPMI 
1640 culture media supplemented with 10% fetal bovine 
serum(HyClone Laboratories, South Logan, UT, USA), 
penicillin and streptomycin in the presence of 10  ng/
mL murine GM-CSF and 1  ng/mL murine IL-4 (both 
from Peprotech, Rocky Hill, NJ, USA). On day 7, BMDCs 
were stimulated with 100  ng/mL LPS (Sigma-Aldrich, 
St. Louis, MO, USA) for 24  h to promote maturation. 
Mature BMDCs were then recovered and washed before 
coculture with T cells.
Coculture of BMDCs with CD4 T cells
Murine CD4 T cell negative isolation kit (Miltenyi Bio-
tech, Cambridge, MA, USA) was used to purify CD4 T 
cells from splenic single cell suspension following the 
manufacturer’s instructions. The purity of purified CD4 T 
cells was typically between 90 and 95%, as determined by 
flow cytometry analysis. After purification, 1 × 106 CD4 
T cells were cocultured with 1 × 105 allogeneic BMDCs 
in triplicates in 24-well plates at 37 °C in a 5% CO2 incu-
bator for up to 6  days. Echinomycin was supplemented 
once daily in the media at 1  nM of final concentration. 
Media supplemented with DMSO at the same volume of 
that in echinomycin dilution was used as media control.
ELISA
At indicated time points of cell culture, supernatants 
were collected and preserved at −20 °C. Concentrations 
of cytokines in culture supernatants were determined by 
using mouse IL-2, IL-10, IL-17A and IFN-γ ELISA kits 
according to the manufacturer’s instructions (all from 
R&D Systems, Minneapolis, MN, USA).
Flow cytometry staining and analysis
Unless otherwise specified, all reagents for flow cytom-
etry were purchased from BD Biosciences (San Jose, CA, 
USA). For extracellular staining of CD4 T cells, anti-
mouse H2Kb-FITC, anti-mouse CD3-V450, anti-mouse 
CD4-AF700, and anti-mouse CD25-APC antibodies were 
used. Fox extracellular staining of BMDCs, anti-mouse 
MHC-II-AF700 (eBioscience, San Diego, CA, USA), anti-
mouse CD86-APC and anti-mouse CD40-FITC were 
used. For intracellular staining of Foxp3, anti-mouse 
Foxp3-PE antibody was used after fixation and permeabi-
lization of cells with Foxp3/Transcription Factor Staining 
Buffer Set from eBioscience (San Diego, CA, USA). For 
intracellular staining of IL-17 and IFN-γ, cells were cul-
tured in the presence of GolgiPlug (1:400) for 5 h before 
harvest. After fixation and permeabilization, cells were 
stained with anti-mouse IL-17A-PE or anti-mouse IFN-γ 
PE antibodies. For T cell proliferation analysis purified 
CD4 T cells were stained with CFSE (5  µM; eBiosci-
ence, San Diego, CA, USA) and cultured alone or with 
allogeneic BMDCs for 5  days. To determine the apop-
tosis of A20 cells, Annexin V Apoptosis Detection Kit 
(eBioscience, San Diego, CA, USA) was used. Cells were 
acquired on a LSR II flow cytometer (BD Biosciences, San 
Jose, CA, USA). Data were analyzed by using FlowJo soft-
ware version 10 (TreeStar, Ashland, OR, USA), except for 
CFSE T cell proliferation analysis where FlowJo software 
version 7.6.1 (TreeStar, Ashland, OR, USA) was used.
Murine aGVHD and GVL models
To generate murine aGVHD model, Balb/c mice were 
lethally irradiated with 850 cGy γ-ray. Immediately after 
irradiation, mice were infused with 5  ×  106 bone mar-
row cells supplemented with 1 × 106 splenic T cells from 
C57BL/6 mice via the tail vein. For syngeneic HSCT con-
trol, identical numbers of bone marrow cells and splenic 
T cells from Balb/c mice were infused instead. EasySep 
Mouse T Cell Isolation Kit (STEMCELL Technologies, 
Vancouver, BC, Canada) was used to purify splenic T 
cells according to the manufacturer’s instructions. To 
generate murine GVL model, 1  ×  106 A20 cells were 
supplemented to bone marrow graft of either Balb/c 
(syngeneic) or C57BL/6 (allogeneic) mice as mentioned 
above, and infused into lethally irradiated Balb/c mice. 
Echinomycin was intraperitoneally injected at 5  µg/kg 
once every other day starting from day 1 after HSCT till 
moribund appearance or through the end of observa-
tion. PBS supplemented with DMSO at the same volume 
of that in echinomycin dilution was used as vehicle con-
trol. After HSCT, mice were monitored daily for physi-
cal appearance and body weight. GVHD score was given 
weekly based on weight loss, posture, activity, fur texture, 
and skin integrity as previously described [27]. In experi-
ments shown in Fig.  5d, Balb/c mice were sublethally 
irradiated with 500 cGy γ-ray and infused with 1 ×  106 
A20 cells via the tail vein to generate a murine leukemia 
model.
Statistical analysis
Two-tailed Student’s t test was used for statistical com-
parison between two groups. Wilcoxon rank test was 
used for the comparison of survival curves. All statisti-
cal analysis was performed by using the GraphPad Prism 
software (version 6.01; GraphPad Software, La Jolla, CA, 
USA). Values of P  <  0.05 were considered statistically 
significant.
Results
HIF‑1α inhibitor echinomycin increases Treg development 
and diminishes alloantigen‑specific T helper cell responses 
ex vivo
To determine the impact of HIF-1α inhibition on alloan-
tigen-specific CD4 T cell responses, we cultured BMDCs 
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of Balb/c mice with allogeneic splenic CD4 T cells puri-
fied from C57BL/6 mice, in the presence of the HIF-1α 
inhibitor echinomycin. By using the flow cytometry gat-
ing strategy shown in Additional file  1: Figure S1a, fre-
quency of various CD4 T cell subsets including Foxp3+, 
IL-17+, and IFN-γ+ cells in total CD4 T cells was deter-
mined. On day 6 of culture, the average frequency of 
CD25+Foxp3+ cells in CD4 T cells in echinomycin treat-
ment group was 20.3%, which was significantly higher 
than that of 9.6% in control group (Fig.  1a; P  <  0.001). 
Notably, in our experiments Foxp3+ cells represented 
around 80% of CD25+ CD4 T cells (Additional file  1: 
Figure S1b). In contrast to the increased frequency of 
CD25+Foxp3+ CD4 T cells, the average frequency of 
IL-17+ CD4 T cells in echinomycin treatment group 
was 0.2%, which was significantly lower than that of 
1.1% in control group (Fig. 1a; P < 0.05). Similar to Th17 
responses, the average frequency of IFN-γ+ CD4 T cells 
in echinomycin treatment group was 17.5%, which was 
significantly lower than that of 32.0% in control group 
(Fig. 1a; P < 0.01). Kinetic analysis on the absolute num-
ber of CD4 T cell subsets on days 0, 3 and 6 showed 
that the numbers of all the three CD4 T cell subsets 
were increased after coculture with allogeneic BMDCs 
(Fig. 1b; P < 0.05 or P < 0.01, as indicated in the figure). 
In line with the frequencies of CD4 T cell subsets, there 
were significantly higher number of CD25+Foxp3+ CD4 
T cells but significantly lower number of IL-17+ and IFN-
γ+ CD4 T cells in echinomycin treatment group on days 
3 and 6 but not on day 0 immediately after coculture 
(Fig. 1b; P < 0.05 or P < 0.01, as indicated in the figure). 
There was no increase in numbers of CD4 T cell sub-
sets on day 3 or day 6 of culture when CD4 T cells were 
cocultured with syngeneic BMDCs (data not shown). 
These data suggest that HIF-1α inhibition increases Treg 
development and reduces Th17 and Th1 responses dur-
ing alloantigen-specific CD4 T cell responses ex vivo.
We went on to determine the impact of echinomycin 
on the proliferation of CD4 T cells during alloantigen-
specific responses. Flow cytometry analysis on CFSE 
dilution showed reduced CD4 T cell proliferation in 
echinomycin treatment group on day 5 of coculture with 
allogeneic BMDCs (Fig. 1c; Additional file 1: Figure S2a). 
Further analysis on proliferation data demonstrated that 
in the two groups there was similar frequency of CD4 
T cells went into proliferation (Additional file  1: Figure 
S2b). By combining intracellular flow cytometry stain-
ing and CFSE dilution assay, we observed that in CD4 T 
cells that went into proliferation, there were significantly 
higher frequency of Foxp3+ CD4 T cells but significantly 
lower frequencies of IL-17+ and IFN-γ+ CD4 T cells in 
echinomycin treatment group as compared with media 
control group (Additional file 1: Figure S2c). These data 
further suggest that echinomycin drives alloantigen-spe-
cific CD4 T cells into a regulatory T cell-skewed differ-
entiation. As a result, frequency of regulatory T cells in 
CD4 T cells was increased and Th17 and Th1 responses 
were inhibited. Consistent to the changes in T cell sub-
sets and proliferation after echinomycin treatment, 
cytokine analysis on days 0, 3 and 6 of culture showed 
that there were significantly increased IL-10 production 
but significantly reduced IL-17, IFN-γ, and IL-2 produc-
tion in echinomycin treatment group on days 3 and 6 of 
culture (Fig. 1d; P < 0.05 or P < 0.01, as indicated in the 
figure). To exclude the possibility that echinomycin may 
reduce the alloantigen presentation capacity by BMDCs, 
we determined activation markers including MHC-II, 
CD86, and CD40 expression in BMDCs cocultured with 
CD4 T cells in the absence or presence of echinomycin. 
There were no differences in MHC-II, CD86, or CD40 
expression in BMDCs between two groups (Additional 
file 1: Figure S3). Thus our data suggest that inhibition of 
HIF-1α by echinomycin reduces the magnitude of alloan-
tigen-specific CD4 T cell responses by increasing the 
development of Tregs, resulting in reduced CD4 T cell 
proliferation and development of alloantigen responding 
CD4 T cells toward Th17 and Th1.
HIF‑1α inhibitor echinomycin reduces aGVHD in mice
We next explored whether this inhibition of alloantigen-
specific CD4 T cell responses ex vivo by echinomycin can 
be translated into reduced aGVHD. By administration of 
echinomycin following allo-HSCT in a murine aGVHD 
model, we evaluated the potential impact of echinomycin 
(see figure on next page.)  
Fig. 1 HIF-1α inhibitor echinomycin increases regulatory T cell development during alloantigen-specific CD4 T cell responses ex vivo. Purified 
splenic CD4 T cells from C57BL/6 mice were cocultured with BMDCs of Balb/c mice. On days 0 (immediately after coculture), 3, and 6 of culture, 
cells were recovered for intracellular staining and flow cytometry analysis. Representative plots and frequencies of intracellular Foxp3, IL-17, or 
IFN-γ expression in CD4 T cells on day 6 are shown in a. Numbers in flow cytometry plots represent mean ± SD frequency (%) of Foxp3+, IL-17+, or 
IFN-γ+ cells in CD4 T cells. Absolute numbers of Foxp3+, IL-17+, or IFN-γ+ CD4 T cells per well on days 0, 3, and 6 are shown in b. c Proliferation of 
CD4 T cells cultured alone (T), with allogeneic DCs (T + DC), or with allogeneic DCs at the presence of echinomycin (T + DC + echinomycin), on 
day 5 of culture is indicated by CFSE dilution analysis. Numbers in flow cytometry plots represent frequency (%) in total CD4 T cells. d Concentra-
tions of cytokines in the supernatant on days 0, 3 and 6 of culture are shown. ND not detected in either group. Bar graphs are shown as mean ± SD. 
*P < 0.05, **P < 0.01, ***P < 0.001. Data are representatives of three independent experiments with triplicate wells in each group
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on aGVHD outcomes. As shown in Fig.  2a, echinomy-
cin treatment significantly prolonged the survival of 
mice following allo-HSCT (P  <  0.001). Consistent with 
the prolonged survival, GVHD scores were reduced in 
echinomycin treated mice following allo-HSCT, though 
the differences were not statistically significant in the first 
2 weeks (days 7 and 14; Fig. 2b). And the GVHD scores 
were significantly reduced in echinomycin treated mice 
from week 3 through week 7 (days 21–49), as demon-
strated by notably reduced body weight loss, hunched 
posture, ruffled fur, as well as increased activity (Fig. 2b; 
Additional file  1: Figure S4a–c; P  <  0.05 or P  <  0.01, as 
indicated in the figure). These data suggest that HIF-1α 
inhibition by echinomycin treatment in  vivo improves 
aGVHD outcomes as evidenced by prolonged survival of 
mice and reduced GVHD scores following allo-HSCT.
HIF‑1α inhibitor echinomycin increases Treg development 
and diminishes Th17 and Th1 responses during aGVHD
To further explore whether the reduced aGVHD in 
echinomycin treated mice following allo-HSCT was 
associated with increased Tregs and/or diminished 
Th17 and Th1 responses as we observed in our ex  vivo 
culture system, we determined the number of the three 
CD4 T cell subsets on days 14 and 21 in the spleen and 
mesenteric lymph nodes (MLN) by using flow cytom-
etry analysis. On day 14 following allo-HSCT, there were 
significantly increased number of CD25+Foxp3+ CD4 
T cells and significantly reduced number of IL-17+ and 
IFN-γ+ CD4 T cells in the spleen of echinomycin treated 
mice (Fig. 3a; P < 0.05, or as indicated in the figure). In 
MLN, there was significantly reduced number of IL-17+ 
CD4 T cells (P  <  0.001) in echinomycin treated mice, 
though there were no significant differences in the num-
ber of CD25+Foxp3+ or IFN-γ+ CD4 T cells (Fig.  3b). 
On day 21 following allo-HSCT, there were significantly 
increased number of CD25+Foxp3+ CD4 T cells and sig-
nificantly reduced number of IL-17+ and IFN-γ+ CD4 T 
cells in both the spleen and MLN of echinomycin treated 
mice (Fig. 3c, d; P < 0.05, or as indicated in the figure). 
These data demonstrated that reduced aGVHD by 
HIF-1α inhibitor treatment in  vivo was associated with 
increased Treg development and diminished Th17 and 
Th1 responses during aGVHD pathogenesis.
HIF‑1α inhibitor echinomycin preserves GVL effects
To evaluate the impact of echinomycin on GVL effects 
that are critically required for the eradication of resid-
ual leukemia cells, we supplemented A20 leukemia 
cells to the HSC graft, followed by echinomycin treat-
ment as mentioned in our aGVHD model. As shown 
in Fig.  4, mice receiving syngeneic HSCT (syn-HSCT) 
and A20 cells died within 40  days post HSCT regard-
less of whether echinomycin was administered. Survival 
of mice receiving allo-HSCT  +  A20 plus echinomycin 
treatment was significantly prolonged as compared with 
mice receiving syn-HSC + A20 plus echinomycin treat-
ment (P < 0.001), indicating the presence of GVL effect 
in echinomycin treated mice following allo-HSCT. More-
over, in mice receiving allo-HSCT +  A20 cells, survival 
was significantly prolonged in echinomycin treated group 
as compared to that of vehicle group (P  <  0.01). These 
findings suggest that echinomycin treatment preserves 
GVL effect and thus prolongs leukemia free survival of 
mice via reducing aGVHD following allo-HSCT.
Echinomycin does not inhibit A20 growth in vivo
HIF-1α inhibition by echinomycin has been shown 
to inhibit cell proliferation and induce apoptosis in a 
number of malignant cell lines including myeloid and 
Fig. 2 HIF-1α inhibitor echinomycin reduces acute GVHD in mice. Lethally irradiated Balb/c mice were infused with syngeneic or allogeneic bone 
marrow cells and splenic T cells from Balb/c (syn-HSCT) or C57BL/6(allo-HSCT) mice. Following HSCT, mice were treated with vehicle or echino-
mycin, and observed daily through day 70 post HSCT for survival (a). ***P < 0.001; allo-HSCT vehicle vs allo-HSCT echinomycin. GVHD scores were 
given weekly based on weight loss, posture, activity, fur texture, and skin integrity (b). Data in b are shown as mean ± SEM. *P < 0.05, **P < 0.01; 
allo-HSCT vehicle vs allo-HSCT echinomycin. Data are representatives of two independent experiments with n = 5 in syn-HSCT groups and n = 12 
in allo-HSCT groups
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lymphoid leukemia cell lines [28–31]. Thus the pro-
longed survival in echinomycin treated mice following 
allo-HSCT plus A20 infusion might due to direct inhibi-
tion of A20 by echinomycin. Although our data in Fig. 4 
showed that echinomycin may not have anti-leukemia 
effect on A20 following a syngeneic HSCT, we used both 
in vitro and in vivo non-HSCT A20 leukemia models to 
further address whether echinomycin inhibit A20 cells 
growth and/or apoptosis in our experimental systems. 
We cultured A20 cells in vitro in the presence of increas-
ing concentrations of echinomycin from 0 to 1 nM. Rep-
resentative pictures of colony formation by A20 cells 
showed that after culture with echinomycin of 0.01 and 
0.1 nM there was no notable reduction in the size of sin-
gle colony (Fig.  5a). However after culture with echino-
mycin at 1 nM, the size of single colony formed by A20 
cells was reduced (Fig. 5a). The numbers of colonies per 
well were not different across all echinomycin concentra-
tions we used (Fig. 5b). These data suggest echinomycin 
treatment inhibits A20 cell growth in  vitro only at high 
Fig. 3 HIF-1α inhibitor echinomycin increases number of Tregs in lymphoid organs in aGVHD mice. Lethally irradiated Balb/c mice were infused 
with allogeneic bone marrow cells and splenic T cells from C57BL/6 mice to generate aGVHD. Mice were treated with vehicle or echinomycin, and 
sacrificed on days 14 or 21. Intracellular expression of Foxp3, IL-17, or IFN-γ in donor-derived CD4 T cells in the spleen and MLN were determined. 
Number of CD25+Foxp3+, IL-17+, or IFN-γ+ CD4 T cells on day 14 in the spleen (a) and MLN (b), as well as on day 21 in the spleen (c) and MLN (d) 
are shown. Bar graphs are shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data are representatives of three independent 
experiments with n = 5 per group
Fig. 4 HIF-1α inhibitor echinomycin preserves GVL effect and 
improved leukemia-free survival. Lethally irradiated Balb/c mice were 
infused with A20 leukemia cells plus syngeneic or allogeneic bone 
marrow cells and splenic T cells from Balb/c (syn-HSCT) or C57BL/6 
(allo-HSCT) mice. Mice were treated with vehicle or echinomycin, 
and observed daily through day 70 post HSCT. Survival of animals 
is shown. ***P < 0.001, allo-HSCT + A20 echinomycin vs syn-
HSCT + A20 echinomycin; **P < 0.01, allo-HSCT + A20 echinomycin 
vs allo-HSCT + A20 vehicle. Data are representatives of two inde-
pendent experiments with n = 8–11 per group
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Fig. 5 Impact of echinomycin on leukemia cell growth in vitro and in vivo. A20 leukemia cells were pre-treated with various concentrations of 
echinomycin in vitro, followed by colony forming analysis. Pictures of representative single colony (a) and number of colonies (b) formed by A20 
cells are shown. In b, data are shown as mean ± SD. c Shows representative flow cytometry dot plots on the apoptosis of A20 leukemia cells treated 
with various concentrations of echinomycin in vitro. Numbers in dot plots represent frequency (%) of cells in the indicated quadrants in total A20 
cells. d Sub-lethally irradiated Balb/c mice were treated with echinomycin, or infused with A20 cells followed by either vehicle or echinomycin treat-
ment. Survival curves of mice are shown. Data in a, b, and c are representatives of three independent experiments with triplicate wells per group. 
Data in d are representative of two independent experiments with n = 5 per group
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concentrations. Flow cytometry analysis of Annex V and 
PI showed that there was no increased apoptosis or cell 
death in A20 cells after culture in the presence of up to 
1 nM echinomycin (Fig. 5c). Importantly, in vivo admin-
istration of echinomycin did not prolong the survival of 
mice infused with A20 (Fig. 5d). These data further dem-
onstrate that in our experimental system echinomycin 
does not significantly inhibit the growth of A20 leukemia 
cells in vivo. These findings thus further support our con-
clusion that treatment with HIF-1α inhibitor echinomy-
cin preserves GVL effect.
Discussion
Separation of GVHD and GVL has been the focus in allo-
HSCT studies for decades [2, 4]. Despite of significant 
improvements in both basic studies and clinical practice 
in this field, novel GVHD prophylactic strategies that 
are superior in efficacy, cost effective, less technically 
demanding, and without compromising GVL effect are 
still in urgent need [1, 2]. Here by using murine models 
of aGVHD and GVL we show that the HIF-1α inhibi-
tor echinomycin reduces aGVHD and preserves GVL 
effect. The reduction of aGVHD by echinomycin treat-
ment is associated with increased Treg development and 
diminished alloantigen-specific Th17 and Th1 responses 
in  vivo. As a result, prophylactic echinomycin treat-
ment prolongs leukemia free survival of mice following 
allo-HSCT.
HIF-1α is a transcription factor that, in CD4 T cells, 
directly binds to RORγt gene to activate its transcrip-
tion and cooperates with RORγt and p300 to activate 
IL-17A gene transcription [18]. As a result, HIF-1α plays 
a positive role in Th17 differentiation and is required in 
the long term persistence of human Th17 after adoptive 
transfer into immunodeficient mice [18, 24]. Concur-
rently, HIF-1α plays a negative role in Treg development 
via directly binding to Foxp3 and target Foxp3 protein 
to degradation. Such a role of HIF-1α in Th17/Treg bal-
ance is further evidenced by the findings that mice with 
HIF-1α deficiency specifically in CD4 T cells were resist-
ant to autoimmune encephalomyelitis (EAE), a Th17 
dependent disease [18]. And this EAE resistant phe-
notype is associated with reduced Th17 responses and 
increased number of Tregs [18]. Given the contradic-
tory roles of Tregs and Th17 in aGVHD, we hypothesize 
that pharmacological inhibition of HIF-1α may help to 
reduce aGVHD via increasing Treg-mediated immune 
homeostasis and diminishing Th17 responses. To test 
this hypothesis we started with an ex vivo culture system 
to determine the impact of the HIF-1α inhibitor echin-
omycin on alloantigen-specific CD4 T cell responses. 
When splenic CD4 T cells were cultured with allogeneic 
BMDCs, there were increased numbers of Tregs on days 
3 and 6 as compared with day 0. The increased number 
of Tregs in the culture indicated the expansion of pre-
existing splenic natural Tregs and/or the development 
of alloantigen-specific inducible Tregs. Not unexpect-
edly, Th17 and to a much larger extent Th1 responses 
increased over time in the culture. Supplementation of 
echinomycin, a small molecule inhibitor of HIF-1α, to the 
culture system resulted in significantly increased devel-
opment of Tregs and reduced Th17 and Th1 responses. 
Echinomycin has been shown to reduce the DNA bind-
ing activity of HIF-1α, though it remains unknown but 
possible that echinomycin also reduces protein bind-
ing activities of HIF-1α [23]. Based on our data and 
current information we hypothesize that echinomycin 
increases Treg development at least partially via reduc-
ing the HIF-1α-Foxp3 binding that resulted in reduced 
Foxp3 degradation. And meanwhile echinomycin dimin-
ishes alloantigen-specific Th17 responses via reducing 
HIF-1α binding to RORγt gene and consequently reduc-
ing activation of IL-17A gene transcription. The reduced 
Th1 responses in echinomycin treatment group may be 
explained by the increased number of Tregs and there-
fore augmented regulatory roles of Tregs as a population 
[21]. In line with such an increased number of Tregs in 
the culture, there was reduced CD4 T cell prolifera-
tion in echinomycin treatment group. These changes 
in Treg versus T helper cell development are further 
supported by the respective changes in cytokines IL-2, 
IL-10, IL-17 and IFN-γ in culture supernatant induced by 
echinomycin.
Acute GVHD remains a huge challenge to favora-
ble clinical outcomes following allo-HSCT in leukemia 
patients [2, 4]. It has been clearly shown in both human 
and mouse that systemic inflammation and target tis-
sue damage during aGVHD attribute largely to donor 
T cells that are activated upon recognizing the mis-
matched host major and/or minor HLA (MHC) alleles 
[1, 4]. Indeed, in both human and mouse, depletion of 
T cells from HSC graft resulted in reduced incidence 
and severity of GVHD [9]. Both Th17 and Th1 cells are 
critically required in the initiation and immunopathol-
ogy of aGVHD [6, 7, 32]. Tregs, on the contrary, induce 
immune homeostasis and play regulatory roles in Th1- 
and Th17-mediated inflammation and tissue damage 
[21]. It has been shown that the number of Tregs in HSC 
graft is associated with GVHD [15, 16], and supplemen-
tation of donor Tregs either freshly purified or expanded 
ex  vivo to HSC graft resulted in reduced GVHD [13, 
14]. Thus, these findings underline the harness of donor 
Tregs as a promising prophylactic strategy against 
GVHD. We show here that the HIF-1α inhibitor echino-
mycin reduces murine aGVHD. And such a phenotype 
is associated with increased number of donor Tregs in 
Page 10 of 11Yao et al. J Transl Med  (2017) 15:28 
lymphoid tissues. Our study thus provides a novel phar-
macological strategy that circumvents the costly, time 
consuming, and highly technically demanding clinical 
protocols to enrich and expand Tregs. Compared with 
Treg infusion, such a pharmacological HIF-1α targeting 
strategy might be superior in protecting target organ by 
direct antagonizing Th17 responses.
In addition to GVHD, leukemic relapse remains a 
major obstacle to favorable clinical outcomes following 
allo-HSCT [2]. GVL effect is a key to eradicating resi-
due leukemia cells and preventing leukemia relapse [2, 
3, 5]. Our data showed that although there were reduced 
alloantigen-specific CD4 T cell responses in echinomycin 
treated mice, GVL effect was not weakened. We speculate 
that there is a threshold level of T cell responses required 
for GVL effect to eradicate leukemia cells. And in our 
current study the increased Treg number does not cause 
T cell responses to be below that threshold. Echinomy-
cin has been shown to inhibit malignant cell growth and 
induce apoptosis [28–31]. However, we did not observe 
significant inhibition of A20 leukemia cell growth in vivo 
by our echinomycin treatment regimen. We speculate 
that this is at least partially due to that we used a lower 
dose of echinomycin than previous studies [28, 31]. 
However, our findings in A20 cells did not exclude the 
possibility that in certain leukemia cells HIF-1α inhibi-
tion remains an effective anti-leukemia regimen. Thus, 
our data provide compelling evidence that the HIF-1α 
inhibitor echinomycin preserves GVL effects, presum-
ably via direct targeting HIF-1α. Based on previous data 
that HIF-1α inhibition by echinomycin preferentially 
target leukemia-initiating cells without adverse effects 
on hematopoietic stem cells [28], we further hypothesize 
that HIF-1α inhibition is a promising prophylactic strat-
egy that not only reduces aGVHD and preserves GVL 
but also preferentially targets leukemia-initiating cells 
that helps to further reduce the risk of leukemia relapse.
In conclusion, we have provided evidence that the 
HIF-1α inhibitor echinomycin reduces aGVHD with-
out weakening GVL effect, which is associated with 
increased donor Treg development and reduced alloan-
tigen-specific Th17 and Th1 responses in vivo, resulting 
in significantly prolonged leukemia free survival in mice. 
Our data thus provide new insights in future studies on 
the separation of GVHD and GVL via pharmacological 
inhibition of HIF-1α.
Conclusions
A small molecule HIF-1α inhibitor echinomycin reduces 
aGVHD and preserves GVL effect following allo-HSCT 
in mice. The reduction of aGVHD is associated with 
increased donor Treg development and diminished 
alloantigen-specific Th17 and Th1 responses in vivo. Our 
findings highlight the significance of HIF-1α as a key 
molecular modulator in aGVHD development. Pharma-
cological inhibition of HIF-1α thus represents a prom-
ising aGVHD prophylactic measure that is worthy of 
further study.
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